Momelotinib Dihydrochloride Monohydrate — Drug Intelligence | 6 EU Trials

Filter these 6 trials by condition, phase, country and more.

6 Registered trials

4 Recruiting

1 Completed trials

4 Sponsors

13 Countries

Phase II

Phase I/II

Phase II: 4 Phase I/II: 2

Indications tested

6 total

Phase 2 Study of Momelotinib in Combination with Luspatercept in Participants with Transfusion Dependent Myelofibrosis. Pending

2024-518225-15-00 Phase II 4 countries Glaxosmithkline Research & Development Limited
Momelotinib in VEXAS syndrome Recruiting

2024-519779-24-00 Phase II 1 country Groupe Francophone Des Myelodysplasies
A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting

2024-519928-24-00 Phase II 5 countries Glaxosmithkline Research & Development Limited
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Phase I/II 2 countries iOnctura SA
Phase 1/2 Study of Oral Nuvisertib (TP-3654) in Patients with Myelofibrosis Recruiting

2022-502597-16-00 Phase I/II 13 countries Sumitomo Pharma America Inc.
Extended Access of Momelotinib for Subjects with Myelofibrosis Ended

2023-508018-41-00 Phase II 10 countries Glaxosmithkline Research & Development Limited

Showing 1–6 of 6 trials